Net Income

Vantage's recent triple award win for trust, tech, and social good is more than a trophy. It reveals the new anatomy of a broker's identity.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Ford hits the brakes on its aggressive EV plan, pivoting to profitable hybrids and a bold new venture in battery energy storage. What does this mean?

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Beijing touts its Sanjiangyuan project as a win for ecology and herders. But beyond the state narrative lies a complex story of coercion and cultural risk.

A popular countertop choice is fueling a deadly, incurable lung disease among workers, sparking a public health crisis and a race for safer alternatives.

A new collaboration aims to transform market noise into actionable foresight, moving beyond simple bets to offer a unified view of the global economy.

An ISG report names Rackspace a leader in AI-driven cloud services, revealing how it helps midmarket firms master cost, complexity, and security.

Sweeping reforms pulled Florida's property insurance market from the brink of collapse. We decode the fixes, the capital influx, and the risks that still loom.

Voxel's AI transforms cameras into proactive safety systems, slashing injuries by 91% and proving that workplace safety is a powerful form of preventative care.

AECOM's win on the GSA OASIS+ contract is more than a deal; it's a strategic move reshaping federal services and securing its role in national projects.

Quebec food distributor Colabor Group fails to secure a financial lifeline, risking creditor protection and threatening a major regional supply chain disruption.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

A new FDA clearance for its AI software enhances Hyperfine's portable MRI, positioning it to disrupt the lucrative stroke diagnostics market. Here's why.

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?